Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
This marks the first partnership between Pfizer and Cipla in India
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
Subscribe To Our Newsletter & Stay Updated